Repository Corticotropin Injection in Keratoconjunctivitis Sicca
Status:
Withdrawn
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to assess repository corticotropin injection (RCI) in the
form of H.P. Acthar Gel in patients with severe keratoconjunctivitis sicca (KCS, or dry eye
disease). This pilot study is a non-randomized, open-label, interventional study to assess
the efficacy and timeline of RCI for the treatment of severe KCS recalcitrant to conventional
therapy. The purpose is to acquire preliminary data to support and guide the design of a
future, double-masked, randomized, controlled clinical trial.